Literature DB >> 24436515

Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.

Sanjay Gupta1.   

Abstract

Hepatic metastases, which are frequently seen in patients with neuroendocrine tumors (NETs), have a major adverse impact on the patient's quality of life and survival. Surgery is the treatment of choice for hepatic metastases but is possible in only a small percentage of patients. Systemic chemotherapy yields disappointing results. Somatostatin analogs are effective in controlling symptoms in many of these patients; however, the disease can become refractory to treatment. Transcatheter intra-arterial liver-directed therapies, such as hepatic artery embolization, chemoembolization, and radioembolization are frequently used in patients with NETs metastatic to the liver, especially in patients with refractory, unresectable, or recurrent disease. These treatments are effective in palliating the hormonal symptoms as well as achieving objective tumor responses. This review focuses on the technique, safety, and clinical efficacy of hepatic artery embolization, chemoembolization, and radioembolization in patients with metastatic NETs.

Entities:  

Keywords:  chemoembolization; interventional radiology; metastases; neuroendocrine; radioembolization

Year:  2013        PMID: 24436515      PMCID: PMC3700796          DOI: 10.1055/s-0033-1333651

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  66 in total

1.  Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria.

Authors:  Daniel B Brown; Jennifer E Gould; Debra A Gervais; S Nahum Goldberg; Ravi Murthy; Steven F Millward; William S Rilling; Jean-Francois S Geschwind; Riad Salem; Suresh Vedantham; John F Cardella; Michael C Soulen
Journal:  J Vasc Interv Radiol       Date:  2009-07       Impact factor: 3.464

2.  Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.

Authors:  Mary K G McStay; Dave Maudgil; Martin Williams; Jonathan M Tibballs; Anthony F Watkinson; Martyn E Caplin; John R Buscombe
Journal:  Radiology       Date:  2005-09-28       Impact factor: 11.105

3.  Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.

Authors:  B Wängberg; G Westberg; U Tylén; L Tisell; S Jansson; O Nilsson; V Johansson; T Scherstén; H Ahlman
Journal:  World J Surg       Date:  1996-09       Impact factor: 3.352

4.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

5.  Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma.

Authors:  Y H Kim; J A Ajani; C H Carrasco; P Dumas; W Richli; D Lawrence; V Chuang; S Wallace
Journal:  Cancer Invest       Date:  1999       Impact factor: 2.176

Review 6.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

7.  Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver.

Authors:  G M Mavligit; R E Pollock; H L Evans; S Wallace
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

8.  Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.

Authors:  Sanjay Gupta; James C Yao; Kamran Ahrar; Michael J Wallace; Frank A Morello; David C Madoff; Ravi Murthy; Marshall E Hicks; Jaffer A Ajani
Journal:  Cancer J       Date:  2003 Jul-Aug       Impact factor: 3.360

9.  Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

Authors:  P Ruszniewski; P Rougier; A Roche; P Legmann; A Sibert; S Hochlaf; M Ychou; M Mignon
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

Review 10.  Neuroendocrine tumors: role of interventional radiology in therapy.

Authors:  Michael J Steward; Victoria S Warbey; Anmol Malhotra; Martyn E Caplin; John R Buscombe; Dominic Yu
Journal:  Radiographics       Date:  2008 Jul-Aug       Impact factor: 5.333

View more
  10 in total

Review 1.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

Review 2.  Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

Authors:  Xi-Feng Jin; Matilde P Spampatti; Christine Spitzweg; Christoph J Auernhammer
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

3.  Other non-surgical treatments for liver cancer.

Authors:  Paul Revel-Mouroz; Philippe Otal; Marion Jaffro; Antoine Petermann; Olivier Meyrignac; Pierre Rabinel; Fatima-Zohra Mokrane
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-14

4.  Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.

Authors:  Yan Luo; Ankur Pandey; Mounes Aliyari Ghasabeh; Pallavi Pandey; Farnaz Najmi Varzaneh; Manijeh Zarghampour; Pegah Khoshpouri; Sanaz Ameli; Zhen Li; Daoyu Hu; Ihab R Kamel
Journal:  Eur Radiol       Date:  2019-03-15       Impact factor: 5.315

5.  Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.

Authors:  S Grozinsky-Glasberg; G Kaltsas; M Kaltsatou; N Lev-Cohain; A Klimov; V Vergadis; I Uri; A I Bloom; D J Gross
Journal:  Endocrine       Date:  2018-01-30       Impact factor: 3.633

Review 6.  Liver transarterial embolizations in metastatic neuroendocrine tumors.

Authors:  Louis de Mestier; Magaly Zappa; Olivia Hentic; Valérie Vilgrain; Philippe Ruszniewski
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

7.  Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.

Authors:  Duc Do Minh; Julius Chapiro; Boris Gorodetski; Qiang Huang; Cuihong Liu; Susanne Smolka; Lynn Jeanette Savic; David Wainstejn; MingDe Lin; Todd Schlachter; Bernhard Gebauer; Jean-François Geschwind
Journal:  Eur Radiol       Date:  2017-07-04       Impact factor: 5.315

8.  Retrospective analysis of interventional treatment of hepatic metastasis from gastroenteropancreatic neuroendocrine tumors.

Authors:  Peng Liu; Xu Zhu; Jie Li; Ming Lu; Jiahua Leng; Ying Li; Jiangyuan Yu
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

9.  Treatment options for PNET liver metastases: a systematic review.

Authors:  Giuseppe Nigri; Niccolò Petrucciani; Tarek Debs; Livia Maria Mangogna; Anna Crovetto; Giovanni Moschetta; Raffaello Persechino; Paolo Aurello; Giovanni Ramacciato
Journal:  World J Surg Oncol       Date:  2018-07-14       Impact factor: 2.754

Review 10.  Carcinoid Heart Disease: How to Diagnose and Treat in 2020?

Authors:  Barbara Bober; Marek Saracyn; Maciej Kołodziej; Łukasz Kowalski; Elżbieta Deptuła-Krawczyk; Waldemar Kapusta; Grzegorz Kamiński; Olga Mozenska; Jacek Bil
Journal:  Clin Med Insights Cardiol       Date:  2020-10-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.